Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinomaMarwah Al-Aloosi, Carla Grandori, Shalini Pereira et al.|Frontiers in Oncology|2024Cited by 8
Abstract 4716: Functional precision medicine: Uncovering high actionability in rare cancers beyond genomicsRachele Rosati, Carla Grandori, Payel Chatterjee et al.|Cancer Research|2025Cited by 1
Abstract 3399: Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapiesAmanda M. Prechtl, Carla Grandori, Marwah Al-Aloosi et al.|Cancer Research|2023Cited by 0
Functional precision medicine profiling of patient-derived organoids identifies effective targeted therapies for patients with low-grade serous ovarian carcinomaElizabeth M. Swisher, Carla Grandori, Heidi J. Gray et al.|Gynecologic Oncology|2025Cited by 0